-
What is iMedicus?
iMedicus is Canada’s most innovative livestream CME channel for specialists and family physicians!
Pearls for Primary Care 2023
Pearls for Primary Care Virtual Conference - October 13, 2023
Watch Now!
Hyperkalemia management in Heart Failure - Watch Now!
The New HFrontier: Watch Now!
The New HFrontier: Worsening Heart Failure
upcoming
featured
11:26
Diabetes Update 2022 Podcast Series
Let’s Be Friends: A Collaborative Conversation between Endocrinology and Cardiology
59:51
A Nephro and Cardio Convo: Common Clinical Questions around Anticoagulation in C
A Nephro and Cardio Convo: Common Clinical Questions around Anticoagulation in CKD
06:18
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Efficacy & Safety Data
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Efficacy & Safety Data
03:31
AIM-LO: Non-HDL Cholesterol: Evolving Evidence Leads to a Novel Strategy
AIM-LO: Non-HDL Cholesterol: Evolving Evidence Leads to a Novel Strategy
06:14
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Mechanisms of Action
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Mechanisms of Action
03:14
AIM-LO: Key Tips to Maximize Therapeutic Access for Your Patients
AIM-LO: Key Tips to Maximize Therapeutic Access for Your Patients
04:48
AIM-LO: Engaging With Your Patients about Selection of Injectable Therapies for
Engaging With Your Patients about Selection of Injectable Therapies for LDL-C Reduction
on demand
59:51
A Nephro and Cardio Convo: Common Clinical Questions around Anticoagulation in C
A Nephro and Cardio Convo: Common Clinical Questions around Anticoagulation in CKD
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Dosing FAQs
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Dosing FAQs
06:18
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Efficacy & Safety Data
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Efficacy & Safety Data
03:31
AIM-LO: Non-HDL Cholesterol: Evolving Evidence Leads to a Novel Strategy
AIM-LO: Non-HDL Cholesterol: Evolving Evidence Leads to a Novel Strategy
06:14
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Mechanisms of Action
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Mechanisms of Action
03:14
AIM-LO: Key Tips to Maximize Therapeutic Access for Your Patients
AIM-LO: Key Tips to Maximize Therapeutic Access for Your Patients
04:48
AIM-LO: Engaging With Your Patients about Selection of Injectable Therapies for
Engaging With Your Patients about Selection of Injectable Therapies for LDL-C Reduction
listen now
11:26
Diabetes Update 2022 Podcast Series
Let’s Be Friends: A Collaborative Conversation between Endocrinology and Cardiology
13:33
Diabetes Update 2022 Podcast Series
Incorporating Novel Cardiovascular (Cv) Risk Reduction Strategies for Diabetes Patients: W
